Fractyl Health, Inc. filed a Form 8-K on November 6, 2026, disclosing the appointment of Michael Wartell as an independent Class III director effective November 2, 2026, along with the terms of his compensation agreement.
Key Highlights
- Board expansion: The Board increased in size from nine to ten members to accommodate the appointment.
- Class III director: Wartell's term expires at the Company's 2027 annual meeting of stockholders.
- Monthly cash compensation: Wartell will receive $40,000 per month, payable monthly in advance, with a minimum of three months guaranteed unless he resigns before that period ends.
- Additional daily fee: An extra $3,000 is payable for each day on which Wartell's Board commitments exceed four hours, outside normal Board duties.
- No standard director policy: Wartell will not participate in the Company's Non-Employee Director Compensation Policy.
- Independence confirmed: The Board determined Wartell is independent under NASDAQ listing standards applicable to the Company.
- No committee assignment: As of the filing date, Wartell has not been appointed to, and is not currently expected to be appointed to, any committee of the Board.
Fractyl Health Adds Veteran Credit and Special Situations Investor to Its Board
According to the filing, Fractyl Health (NASDAQ:GUTS) reported that its Board of Directors appointed Michael Wartell as a Class III director on November 2, 2026. The Board simultaneously voted to increase its size from nine to ten members. Wartell's term is set to expire at the Company's 2027 annual meeting of stockholders, or until his successor is duly elected and qualified, or until his earlier resignation or removal.
The filing describes Wartell as the President of Bluerose Associates LLC, with over 35 years of experience investing in opportunistic credit, credit solutions, equities, and special situations. He currently serves on the boards of directors of Aeromexico Group, Kelly Services, Inc., and America's Car-Mart, Inc., according to the disclosure. The Company stated that it believes Wartell's "extensive board advisory expertise qualifies him to serve as one of its directors."
The Director Agreement governing Wartell's service, filed as Exhibit 10.1, provides for cash compensation of $40,000 per month payable in advance, with no fixed term for his Board service. An additional $3,000 per day is payable when his Board commitments exceed four hours outside of normal Board duties. The filing also confirmed there are no reportable related-party transactions under Item 404(a) of Regulation S-K involving Wartell or any member of his immediate family, and that no arrangement with any other person was involved in his selection beyond the Director Agreement itself. Wartell has entered into the Company's standard form of indemnification agreement for directors.
What Was Disclosed
Fractyl Health disclosed the appointment of Michael Wartell as an independent Class III director effective November 2, 2026, the expansion of the Board from nine to ten members, and the terms of a Director Agreement providing $40,000 monthly cash compensation with supplemental daily fees.




Please wait processing your request...